Authors:
Aithal, GP
Craggs, A
Day, CP
Welfare, M
Daly, AK
Mansfield, JC
Hudson, M
Citation: Gp. Aithal et al., Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease, DIG DIS SCI, 46(7), 2001, pp. 1520-1525
Authors:
Mitchell, SA
Grove, J
Spurkland, A
Boberg, KM
Fleming, KA
Day, CP
Schrumpf, E
Chapman, RW
Citation: Sa. Mitchell et al., Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis, GUT, 49(2), 2001, pp. 288-294
Authors:
Aithal, GP
Day, CP
Leathart, JBS
Daly, AK
Citation: Gp. Aithal et al., Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis, PHARMACOGEN, 10(6), 2000, pp. 511-518
Citation: Hl. Reeves et al., The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells, HEPATOLOGY, 31(1), 2000, pp. 95-100
Citation: Gp. Aithal et al., Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions, J HEPATOL, 33(6), 2000, pp. 949-952
Authors:
Reeves, HL
Dack, CL
Peak, M
Burt, AD
Day, CP
Citation: Hl. Reeves et al., Stress-activated protein kinases in the activation of rat hepatic stellatecells in culture, J HEPATOL, 32(3), 2000, pp. 465-472
Authors:
Grove, J
Daly, AK
Bassendine, MF
Gilvarry, E
Day, CP
Citation: J. Grove et al., Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease, GUT, 46(4), 2000, pp. 540-545
Citation: Gp. Aithal et al., Accuracy of hepatic adverse drug reaction reporting in one English health region, BR MED J, 319(7224), 1999, pp. 1541-1541
Citation: M. Dixon et al., Inhibition of rat hepatocyte proliferation by transforming growth factor beta and glucagon is associated with inhibition of ERK2 and p70 S6 kinase, HEPATOLOGY, 29(5), 1999, pp. 1418-1424
Authors:
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
Citation: Gp. Aithal et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, LANCET, 353(9154), 1999, pp. 717-719